Alternative salvage regimens for relapsed/refractory classical Hodgkin's lymphoma

作者：Magyari Ferenc^*; Barna Sandor; Husi Kata; Simon Zsofia; Miltenyi Zsofia; Varoczy Laszlo; Udvardy Miklos; Illes Arpad

来源：Hematology, 2016, 21(7): 404-410.

DOI：10.1080/10245332.2015.1115192

• Classical HL
• Bendamustine
• Brentuximab-vedotin
• Rituximab
• (18)FDG-PET/CT

Objective and importance: Hodgkin's lymphoma (HL) is a well-curable disease. The treatment usually includes combined multiagent conventional chemotherapy and radiotherapy. One-fifth of the patients need repeated treatments because of relapse or primary progressive disease. Those HL patients, who cannot be cured at least with salvage therapy (including autologous haemopoietic stem cell transplantation (auto-HSCT)), have really unfavourable prognosis.
Intervention: For this heavily pretreated subset of HL patients, novel but less toxic treatment strategies should be considered. Brentuximab-vedotin (BV) is a novel targeted treatment option, which was administered after the failure of two different regimens in patients, who were ineligible for auto-HSCT or after the failure of auto-HSCT. Moreover, there are favourable data with chemotherapeutical regimens supplemented with rituximab not only in relapsed but also in newly diagnosed classical HL patients. Bendamustine, an almost forgotten 50-year-old drug, lives its renaissance in the twenty-first century, which can be administered in refractory HL as well. Combination of the 'new' and 'old' drugs might be also helpful.
Conclusion: Our data suggest that rituximab plus bendamustine (supplemented with or without BV) could be a suitable alternative bridging salvage therapy for heavily pretreated HL patients.

• 出版日期2016